journal
https://read.qxmd.com/read/38635139/inflammatory-gene-panel-guiding-the-study-of-genetics-in-inflammatory-bowel-disease
#1
REVIEW
Ryan Xin
Inflammatory bowel disease (IBD) is a complex disease that develops through a sequence of molecular events that are still poorly defined. This process is driven by a multitude of context-dependent genes that play different roles based on their environment. The complexity and multi-faceted nature of these genes make it difficult to study the genetic basis of IBD. The goal of this article is to review the key genes in the pathophysiology of IBD and highlight new technology that can be used in further research...
April 18, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38625642/lifileucel-first-approval
#2
JOURNAL ARTICLE
Susan J Keam
Lifileucel (AMTAGVI™), a one-time autologous T cell therapy derived and expanded from tumour-infiltrating lymphocytes (TIL) from a patient's own tumour, is being developed by Iovance Biotherapeutics, Inc. for the treatment of cancer. Lifileucel was granted accelerated approval based on objective response rate (ORR) in February 2024 in the USA for use in adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor...
April 16, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38616205/estimating-the-prognostic-value-of-the-ntrk-fusion-biomarker-for-comparative-effectiveness-research-in-the-netherlands
#3
JOURNAL ARTICLE
Irene Santi, Heleen Vellekoop, Matthijs M Versteegh, Simone A Huygens, Winand N M Dinjens, Maureen Rutten-van Mölken
OBJECTIVES: We evaluated the prognostic value of the neurotrophic tyrosine receptor kinase (NTRK) gene fusions by comparing the survival of patients with NTRK+ tumours with patients without NTRK+ tumours. METHODS: We used genomic and clinical registry data from the Center for Personalized Cancer Treatment (CPCT-02) study containing a cohort of cancer patients who were treated in Dutch clinical practice between 2012 and 2020. We performed a propensity score matching analysis, where NTRK+ patients were matched to NTRK- patients in a 1:4 ratio...
April 14, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38600343/comment-on-prognostic-value-of-programmed-death-ligand-1-expression-in-solid-tumors-irrespective-of-immunotherapy-exposure-a-systematic-review-and-meta%C3%A2-analysis
#4
LETTER
Jun Ma, Wei Han
No abstract text is available yet for this article.
April 10, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38581611/molecular-dynamic-simulations-to-determine-individualized-therapy-tetrabenazine-for-the-gnao1-encephalopathy-e246k-variant
#5
JOURNAL ARTICLE
Raffaele Falsaperla, Vincenzo Sortino, Simona Domenica Marino, Ausilia Desiree Collotta, Carmela Gammeri, Federica Maria Sipala, Giovanni Li Volti, Martino Ruggieri, Simone Ronsisvalle
INTRODUCTION: GNAO1 encephalopathy is characterized by severe hypotonia, psychomotor retardation, epilepsy, and movement disorders. Genetic variations in GNAO1 have been linked to neurological symptoms including movement disorders like dystonia. The correlation between the E246K mutation in the Gα subunit and aberrant signal transduction of G proteins has been established but no data are reported regarding the efficacy of medical treatment with tetrabenazine. METHODS: Molecular modeling studies were performed to elucidate the molecular mechanisms underlying this mutation...
April 6, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38568469/diagnostic-approaches-to-investigate-jak2-unmutated-erythrocytosis-based-on-a-single-tertiary-center-experience
#6
JOURNAL ARTICLE
Youngeun Lee, Soo Hyun Seo, Jinho Kim, Sang-A Kim, Ji Yun Lee, Jeong-Ok Lee, Soo-Mee Bang, Kyoung Un Park, Sang Mee Hwang
INTRODUCTION: Erythrocytosis is attributed to various clinical and molecular factors. Many cases of JAK2-unmutated erythrocytosis remain undiagnosed. We investigated the characteristics and causes of JAK2-unmutated erythrocytosis. METHODS: We assessed the clinical and laboratory results of patients with erythrocytosis without JAK2 mutations and performed targeted next-generation sequencing (NGS) panels for somatic and germline mutations. RESULTS: In total, 117 patients with JAK2-unmutated erythrocytosis were included...
April 3, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38555542/advances-in-radioligand-theranostics-in-oncology
#7
REVIEW
Ismaheel O Lawal, Sofiullah O Abubakar, Honest Ndlovu, Kgomotso M G Mokoala, Stuart S More, Mike M Sathekge
Theranostics with radioligands (radiotheranostics) has played a pivotal role in oncology. Radiotheranostics explores the molecular targets expressed on tumor cells to target them for imaging and therapy. In this way, radiotheranostics entails non-invasive demonstration of the in vivo expression of a molecular target of interest through imaging followed by the administration of therapeutic radioligand targeting the tumor-expressed molecular target. Therefore, radiotheranostics ensures that only patients with a high likelihood of response are treated with a particular radiotheranostic agent, ensuring the delivery of personalized care to cancer patients...
March 31, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38538969/in-vivo-lnp-crispr-approaches-for-the-treatment-of-hemophilia
#8
JOURNAL ARTICLE
Jeong Hyeon Lee, Jeong Pil Han
Hemophilia is a genetic disorder that is caused by mutations in coagulation factor VIII (hemophilia A) or IX (hemophilia B) genes resulting in blood clotting disorders. Despite advances in therapies, such as recombinant proteins and products with extended half-lives, the treatment of hemophilia still faces two major limitations: the short duration of therapeutic effect and production of neutralizing antibodies against clotting factors (inhibitor). To overcome these limitations, new hemophilia treatment strategies have been established such as gene therapy, bispecific antibody, and rebalancing therapy...
March 28, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38530633/unwinding-helicase-mcm-functionality-for-diagnosis-and-therapeutics-of-replication-abnormalities-associated-with-cancer-a-review
#9
REVIEW
Arathi Radhakrishnan, Ritwik Gangopadhyay, Chandresh Sharma, Raj Kishor Kapardar, Nilesh Kumar Sharma, Rajpal Srivastav
The minichromosome maintenance (MCM) protein is a component of an active helicase that is essential for the initiation of DNA replication. Dysregulation of MCM functions contribute to abnormal cell proliferation and genomic instability. The interactions of MCM with cellular factors, including Cdc45 and GINS, determine the formation of active helicase and functioning of helicase. The functioning of MCM determines the fate of DNA replication and, thus, genomic integrity. This complex is upregulated in precancerous cells and can act as an important tool for diagnostic applications...
March 26, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38459249/identification-of-plasmatic-microrna-206-as-new-predictor-of-early-recurrence-of-atrial-fibrillation-after-catheter-ablation-using-next-generation-sequencing
#10
JOURNAL ARTICLE
Filip Šustr, Táňa Macháčková, Martin Pešl, Jana Svačinova, Karolína Trachtová, Zdeněk Stárek, Bohuslav Kianička, Ondřej Slabý, Jan Novák
BACKGROUND: Catheter ablation (CA) of atrial fibrillation (AF) is indicated in patients with recurrent and symptomatic AF episodes. Despite the strict inclusion/exclusion criteria, AF recurrence after CA remains high. Identification of a novel biomarker that would predict AF recurrence would help to stratify the patients. The aim of the study was to seek novel biomarkers among the plasmatic microRNAs (miRNAs, miRs). METHODS: A prospective monocentric study was conducted...
March 8, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38446353/lutetium-177-labelled-anti-psma-monoclonal-antibody-lu-tlx591-therapy-for-metastatic-prostate-cancer-treatment-toxicity-and-outcomes
#11
JOURNAL ARTICLE
Hanh Nguyen, Kathryn Hird, Joe Cardaci, Steven Smith, Nat P Lenzo
INTRODUCTION: Whilst prostate cancer is the fourth most common cancer globally, effective therapies for patients with advanced disease are lacking. In recent years, interest in using theranostic agents to treat castrate-resistant prostate cancer (CRPC) and metastatic prostate cancer has emerged. Lu-TLX591 monoclonal antibody is a potential agent of significance; however, to date, reports on its toxicity and efficacy have been limited to small clinical trials in heavily pretreated patients...
March 6, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38376655/comment-on-prognostic-and-clinical-significance-of-human-leukocyte-antigen-class-i-expression-in-breast-cancer-a-meta%C3%A2-analysis
#12
LETTER
Wei Han, Li-Zhou Shi, Yu-Wei Zhang, Hao-Nan Wang
No abstract text is available yet for this article.
February 20, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38341835/adora3-a-key-player-in-the-pathogenesis-of-intracranial-aneurysms-and-a-potential-diagnostic-biomarker
#13
JOURNAL ARTICLE
Rui-Ting Hu, Hao-Wei Deng, Wen-Bin Teng, Shao-Dan Zhou, Zi-Ming Ye, Zi-Mei Dong, Chao Qin
BACKGROUND: The effects of genes on the development of intracranial aneurysms (IAs) remain to be elucidated, and reliable blood biomarkers for diagnosing IAs are yet to be established. This study aimed to identify genes associated with IAs pathogenesis and explore their diagnostic value by analyzing IAs datasets, conducting vascular smooth muscle cells (VSMC) experiments, and performing blood detection. METHODS: IAs datasets were collected and the differentially expressed genes were analyzed...
February 11, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38324138/chimeric-genes-causing-11%C3%AE-hydroxylase-deficiency-implications-in-clinical-and-molecular-diagnosis
#14
REVIEW
Paola Concolino
Deficiency of 11β-hydroxylase (11β-OHD) is the second most common cause of congenital adrenal hyperplasia (CAH), accounting for 0.2-8% of all cases. The disease is transmitted as an autosomal recessive trait and the underlying genetic causes of 11β-OHD are primarily small pathogenic variants affecting the CYP11B1 gene coding the 11β-hydroxylase enzyme. However, special events complicate the molecular diagnosis of 11β-OHD such as an unequal crossing over between the CYP11B2 (coding aldosterone synthase enzyme) and CYP11B1 genes...
February 7, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38302842/clostridium-bacteria-harnessing-tumour-necrosis-for-targeted-gene-delivery
#15
JOURNAL ARTICLE
Jan Theys, Adam V Patterson, Alexandra M Mowday
Necrosis is a common feature of solid tumours that offers a unique opportunity for targeted cancer therapy as it is absent from normal healthy tissues. Tumour necrosis provides an ideal environment for germination of the anaerobic bacterium Clostridium from endospores, resulting in tumour-specific colonisation. Two main species, Clostridium novyi-NT and Clostridium sporogenes, are at the forefront of this therapy, showing promise in preclinical models. However, anti-tumour activity is modest when used as a single agent, encouraging development of Clostridium as a tumour-selective gene delivery system...
February 2, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38267771/unraveling-emerging-anal-cancer-clinical-biomarkers-from-current-immuno-oncogenomics-advances
#16
REVIEW
Soledad Iseas, Golubicki Mariano, Louis Gros, Nabil Baba-Hamed, Vincent De Parades, Julien Adam, Eric Raymond, Martin Carlos Abba
Anal squamous cell carcinoma (ASCC) is a rare gastrointestinal malignancy associated with high-risk human papillomavirus (HPV) and is currently one of the fastest-growing causes of cancer incidence and mortality in developed countries. Although next-generation sequencing technologies (NGS) have revolutionized cancer and immuno-genomic research in various tumor types, a limited amount of clinical research has been developed to investigate the expression and the functional characterization of genomic data in ASCC...
January 24, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38261250/the-complement-system-and-c4b-binding-protein-a-focus-on%C3%A2-the-promise-of-c4bp%C3%AE-as-a-biomarker-to-predict-clopidogrel-resistance
#17
REVIEW
Hong-Guang Xie, Li-Ping Jiang, Ting Tai, Jin-Zi Ji, Qiong-Yu Mi
The complement system plays a dual role in the body, either as a first-line defense barrier when balanced between activation and inhibition or as a potential driver of complement-associated injury or diseases when unbalanced or over-activated. C4b-binding protein (C4BP) was the first circulating complement regulatory protein identified and it functions as an important complement inhibitor. C4BP can suppress the over-activation of complement components and prevent the complement system from attacking the host cells through the binding of complement cleavage products C4b and C3b, working in concert as a cofactor for factor I in the degradation of C4b and C3b, and consequently preventing or reducing the assembly of C3 convertase and C5 convertase, respectively...
January 23, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38228954/exagamglogene-autotemcel-first-approval
#18
REVIEW
Sheridan M Hoy
Exagamglogene autotemcel (Casgevy™) is a genetically modified autologous CD34+ cell enriched population. It contains human haematopoietic stem and progenitor cells edited ex vivo by CRISPR/Cas9 (a DNA double strand break-inducing nuclease system) to differentiate into erythroid cells that produce high levels of foetal hemoglobin. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, exagamglogene autotemcel received its first approval on 16 November 2023 in the UK for the treatment of transfusion-dependent β-thalassemia (TDT) in patients aged ≥ 12 years for whom haematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen matched related HSC donor is not available...
January 17, 2024: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38150172/personalizing-oncolytic-immunovirotherapy-approaches
#19
JOURNAL ARTICLE
Georgios M Stergiopoulos, Ianko Iankov, Evanthia Galanis
Development of successful cancer therapeutics requires exploration of the differences in genetics, metabolism, and interactions with the immune system among malignant and normal cells. The clinical observation of spontaneous tumor regression following natural infection with microorganism has created the premise of their use as cancer therapeutics. Oncolytic viruses (OVs) originate from viruses with attenuated virulence in humans, well-characterized vaccine strains of known human pathogens, or engineered replication-deficient viral vectors...
December 27, 2023: Molecular Diagnosis & Therapy
https://read.qxmd.com/read/38133736/acute-fluid-biomarkers-for-diagnosis-and-prognosis-in-children-with-mild-traumatic-brain-injury-a-systematic-review
#20
Armaan K Malhotra, Kentaro Ide, Zaid Salaheen, Quenby Mahood, Jessie Cunningham, Jamie Hutchison, Anne-Marie Guerguerian
BACKGROUND AND OBJECTIVE: Fluid biomarkers have the potential to improve the accuracy of diagnosis and prognosis in children with mild traumatic brain injury. Our primary objective was to assess the diagnostic and prognostic utility of acute blood and fluid biomarkers in children with mild traumatic brain injury. METHODS: We performed a systematic review of the published literature in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology...
December 22, 2023: Molecular Diagnosis & Therapy
journal
journal
41252
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.